Literature DB >> 8840127

Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus.

Y P Maneuf1, J E Nash, A R Crossman, J M Brotchie.   

Abstract

The interaction between GABA (gamma-aminobutyric acid) and cannabinoids in the globus pallidus was investigated by evaluating the effects of delta 9-tetrahydrocannabinol on [3H]GABA uptake into slices of rat globus pallidus. delta 9-Tetrahydrocannabinol caused a concentration-dependent decrease in GABA uptake (51% decrease at 100 microM delta 9-tetrahydrocannabinol, IC50 = 18.95 microM). This effect was reversed in a concentration-dependent manner (IC50 = 11.9 microM) by the cannabinoid receptor antagonist SR 141716A (N-(piperidin-1-yl-)5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-me thyl-1 H-pyrazole-3-arboxiamidehydrochloride. SR 141716A alone did not affect GABA uptake. These results show that cannabinoid receptor activation reduces GABA uptake in the globus pallidus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840127     DOI: 10.1016/0014-2999(96)00326-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.

Authors:  Szabolcs Farkas; Katalin Nagy; Zhisheng Jia; Tibor Harkany; Miklós Palkovits; Sean R Donohou; Victor W Pike; Christer Halldin; Domokos Máthé; László Csiba; Balázs Gulyás
Journal:  Brain Res Bull       Date:  2012-03-07       Impact factor: 4.077

2.  L-type calcium channel mediates anticonvulsant effect of cannabinoids in acute and chronic murine models of seizure.

Authors:  Nima Naderi; Leila Ahmad-Molaei; Ali Mazar-Atabaki; Abdolaziz Ronaghi; Zahra Shirazi-zand; Seyed Mehrdad Motiei-Langroudi; Somayeh Eslahkar
Journal:  Neurochem Res       Date:  2011-09-18       Impact factor: 3.996

3.  Separate and combined effects of the GABA reuptake inhibitor tiagabine and Δ9-THC in humans discriminating Δ9-THC.

Authors:  Joshua A Lile; Thomas H Kelly; Lon R Hays
Journal:  Drug Alcohol Depend       Date:  2011-10-04       Impact factor: 4.492

Review 4.  Endocannabinoid system in neurodegenerative disorders.

Authors:  Balapal S Basavarajappa; Madhu Shivakumar; Vikram Joshi; Shivakumar Subbanna
Journal:  J Neurochem       Date:  2017-07-05       Impact factor: 5.372

5.  Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.

Authors:  C García; C Palomo-Garo; M García-Arencibia; Ja Ramos; Rg Pertwee; J Fernández-Ruiz
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

Review 6.  [Therapeutic use of cannabinoids in neurology].

Authors:  P Schwenkreis; M Tegenthoff
Journal:  Schmerz       Date:  2003-10       Impact factor: 1.107

Review 7.  Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases.

Authors:  Mario van der Stelt; Henrik H Hansen; Wouter B Veldhuis; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Johannes F G Vliegenthart; Harald S Hansen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 8.  Synaptic targets of Δ9-tetrahydrocannabinol in the central nervous system.

Authors:  Alexander F Hoffman; Carl R Lupica
Journal:  Cold Spring Harb Perspect Med       Date:  2013-08-01       Impact factor: 6.915

9.  Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine.

Authors:  Hadi Fathi Moghaddam; Mohammad Javad Khodayar; Seyed Mohammad Zarei Abarghouei; Mehdi Shafiee Ardestani
Journal:  Saudi Pharm J       Date:  2010-05-31       Impact factor: 4.330

10.  Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users.

Authors:  Michael J Wesley; Philip M Westgate; William W Stoops; Thomas H Kelly; Lon R Hays; Joshua A Lile
Journal:  Exp Clin Psychopharmacol       Date:  2018-06       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.